23 May 2013
Keywords: lilly, advance, ly519818, into, ph, iii, ligand
Article | 08 March 2004
Ligand Pharmaceuticals has reported that drug major Eli Lilly is to advance LY519818 into Phase III registration studies. The agent ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 March 2004
22 May 2013
© 2013 thepharmaletter.com